CStone Pharmaceuticals' (HKG:2616) investigational new drug application for CS5007 was rapidly approved by China's National Medical Products Administration in 23 days.
The global multicenter phase I study of the tumor drug began in Australia in June, with the first patient successfully enrolled, and will be conducted in parallel in China, according to a Friday Hong Kong bourse filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments